18h agoThe FlyBEARISH 34General
Archived explainer. For the current picture see today's ORIC page.
Why Is ORIC PHARMACEUTICALS (ORIC) Stock Down Today?
By the Top Tier Newswire AI Desk · October 27, 2026 at 12:03 AM ET · reviewed against 3 wire stories
ORIC PHARMACEUTICALS (ORIC) is down -32.00% in the latest session. Our newswire has captured 3 stories on ORIC across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Oric Pharmaceuticals shares fell 32.00% to close at $8.96. The primary driver was the presentation of prostate cancer drug data by Johnson & Johnson, which weighed on the stock despite a recent price target increase from Stifel.
What Happened
The sharp decline followed the release of new clinical data from Johnson & Johnson regarding its prostate cancer treatments. This development impacted Oric Pharmaceuticals, which is currently unprofitable with a trailing twelve-month EPS of negative $1.35. In a separate move, Stifel raised its price target for Oric from $14 to $18, citing data presented at the ESMO Congress. Stifel maintained a Buy rating on the stock. The company also announced plans to advance enozertinib to a Phase 3 trial and presented preclinical data for rinzimetostat.
What The Data Shows
Oric Pharmaceuticals has a market capitalization of $1.4 billion and a beta of 0.98. The stock trades within a 52-week range of $7.23 to $14.68. Notably, the stock printed 62 fresh 52-week lows on October 26, 2026. Recent insider activity indicates a trend of selling, with five sales totaling $1.5 million in the last 90 days and no purchases. The most recent transactions include sales by CFO Dominic Piscitelli on October 20 and September 28, and a sale by Director Richard A. Heyman on October 1.
What To Watch
Investors will monitor the broader healthcare sector for further reactions to the Johnson & Johnson data. The company’s upcoming progression of enozertinib to Phase 3 trials remains a key catalyst for future valuation.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORIC by the numbers
Last: $8.96Session: -32.00%Coverage: 3 stories / 2 sourcesAI sentiment: 54/100 (mixed)Mkt cap: $1.4B52w: $7.23 to $14.68
The headlines behind the move
21h agoThe FlyBULLISH 64Analyst
Oric Pharmaceuticals price target raised to $18 from $14 at Stifel
1d agoInvesting.com Analyst RatingsBULLISH 64Analyst
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORIC: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ORIC move explainers: 2026-10-27 · 2026-10-26 · 2026-10-23 · 2026-10-20